{"product_id":"prolia-jeringa-60mg-ml-con-1-denosumab","title":"Prolia Syringe 60mg\/ml with 1 (Denosumab)","description":"\u003ch2\u003eCategory\u003c\/h2\u003e\n\u003cp\u003eMedication\u003c\/p\u003e\n\n\u003ch2\u003eLine\u003c\/h2\u003e\n\u003cp\u003eTreatment of bone diseases\u003c\/p\u003e\n\n\u003ch2\u003eBrand\u003c\/h2\u003e\n\u003cp\u003eProlia\u003c\/p\u003e\n\n\u003ch2\u003eMolecule\u003c\/h2\u003e\n\u003cp\u003eDenosumab\u003c\/p\u003e\n\n\u003ch2\u003ePresentation\u003c\/h2\u003e\n\u003cp\u003eSyringe 60 mg\/ml\u003c\/p\u003e\n\n\u003ch2\u003eLaboratory\u003c\/h2\u003e\n\u003cp\u003eAmgen\u003c\/p\u003e\n\n\u003ch2\u003eIndications\u003c\/h2\u003e\n\u003cp\u003eProlia (Denosumab) is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fractures. It is also used in men with osteoporosis and in patients diagnosed with prostate cancer who are receiving androgen deprivation therapy, as well as in patients with breast cancer who are receiving aromatase inhibitor therapy. Additionally, Prolia is indicated for the prevention of fractures in patients with low bone mineral density and in those with a history of osteoporotic fractures. This medication works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption, which helps to improve bone density and reduce the risk of fractures.\u003c\/p\u003e\n\n\u003ch2\u003eComposition\u003c\/h2\u003e\n\u003cp\u003eEach Prolia syringe contains 60 mg of Denosumab in 1 ml of injectable solution.\u003c\/p\u003e\n\n\u003ch2\u003eContraindications\u003c\/h2\u003e\n\u003cp\u003eProlia is contraindicated in patients with untreated hypocalcemia. It should not be used in patients with a history of severe allergic reactions to Denosumab or any of the excipients in the formulation. Additionally, its use is not recommended in patients with active severe infections or in those with immunosuppressive diseases that may increase the risk of infections.\u003c\/p\u003e\n\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\n\u003cp\u003eCaution should be exercised in patients with a history of recurrent infections, as Prolia may increase the risk of infections. It is recommended to monitor blood calcium levels before and during treatment, especially in those at risk of hypocalcemia. The possibility of osteonecrosis of the jaw should also be considered in patients undergoing dental procedures or who have risk factors.\u003c\/p\u003e\n\n\u003ch2\u003eStorage\u003c\/h2\u003e\n\u003cp\u003eStore refrigerated between 2°C and 8°C. Do not freeze. Keep out of reach of children.\u003c\/p\u003e\n\n\u003cp\u003ePrescription required.\u003c\/p\u003e\n\u003cp\u003eConsult your doctor.\u003c\/p\u003e","brand":"Amgen","offers":[{"title":"Default Title","offer_id":45848464687329,"sku":"8715131006303","price":10552.4,"currency_code":"MXN","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0722\/1500\/3361\/files\/planogram__1__164643cc-bae1-4f99-a591-06cd09c0a9e8.jpg?v=1744687964","url":"https:\/\/wecarepharma.mx\/en\/products\/prolia-jeringa-60mg-ml-con-1-denosumab","provider":"WeCare Pharma","version":"1.0","type":"link"}